Announcements
- Sanofi completes Kiadis acquisition
- Sanofi declares the Offer for Kiadis unconditional
- Kiadis employee options committed under the Sanofi Offer
- Kiadis Pharma announces annual results for the year ended December 31, 2020
- Kiadis EGM adopts all resolutions related to the recommended public offer by Sanofi
- Kiadis issues shares to Kreos Capital following agreed conversion of convertible bonds
- Sanofi launches recommended cash offer for all shares in Kiadis
- Kiadis Shareholders give irrevocable commitment to tender 36.6% of the shares under the offer by Sanofi
- Kiadis announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR
- Kiadis draws €20 million from bridge loan with Sanofi
More ▼
Key statistics
On Wednesday, Kiadis Pharma NV (K3P:FRA) closed at 5.42, -0.55% below its 52-week high of 5.45, set on Mar 16, 2021.
52-week range
Markit short selling activity
Open | 5.42 |
---|---|
High | 5.42 |
Low | 5.42 |
Bid | -- |
Offer | -- |
Previous close | 5.42 |
Average volume | 577.27 |
---|---|
Shares outstanding | 42.89m |
Free float | 41.81m |
P/E (TTM) | -- |
Market cap | 233.77m EUR |
EPS (TTM) | -2.14 EUR |
Data delayed at least 15 minutes, as of Apr 21 2021 07:08 BST.
More ▼